466results about How to "Good anti-inflammatory activity" patented technology

Methods and compositions for enhancing the activity and / or duration of action of loteprednol etabonate and other soft anti-inflammatory steroids of the haloalkyl 17α-alkoxycarbonyloxy-11β-hydroxyandrost-4-cn-3-one-17β-carboxylate type and the corresponding Δ1,4-compounds are described. The enhancing agents have the formula:wherein Z1 is carbonyl, β-hydroxymethylene or methylene; R2 is H, —OH or —OCOR3 wherein R3 is C1-5 alkyl; Y is —OH, —SH or —OCOR4 wherein R4 is C1-5 alkyl, cyclopentylethyl or diethylaminoethyl; and the dotted line in ring A indicates that the 1,2-linkage is saturated or unsaturated. Ophthalmic administration in the treatment of dry eye is specifically targeted.

A method and medicament for anticoagulating a patient with a sulfated polysaccharide mixture that demonstrates enhanced anti-inflammatory activity compared to anticoagulation with unfractionated heparin comprising various combinations of fully anticoagulant unfractionated heparin with 2-O desulfated heparin demonstrating reduced anticoagulant activity but enhanced anti-inflammatory actions. The medicament preferably is administered intravenously, by aerosolization or orally. Preferably, the 2-O desulfated heparin medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, normal saline and distilled water. Additionally provided is a method of synthesizing 2-O desulfated heparin in commercially practical quantities for the formulation of an anticoagulant 2-O desulfated heparin and heparin mixture.

There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery.

The invention provides a compound feed capable of improving the fatty liver and body colour of the marine fish. The compound feed comprises a premixed feed, a bile acid, curcumin and betaine, wherein the premixed feed comprises fish meal, soya bean meal, corn gluten meal, high protein flour, corn, shrimp shell meal, monocalcium phosphate, fish oil, liquid phosphatide, vitamin premixes, mineral premixes, and the like. Artificial marine-fish breeding experiments prove that the compound feed provided by the invention can meet the nutritional needs of marine-fish growth, effectively enhance the physique of the marine fish, improve the immunity of the marine fish, reduce the incidence of a fatty liver disease, and improve the body color of the marine fish, so that the body color of the marine fish is bright-colored and close to a wild natural color, thereby enhancing the quality of artificially cultured marine fish.

Variants (mutants) of recombinant activated protein C (APC) or recombinant protein C (prodrug, capable of being converted to APC) that have substantial reductions in anticoagulant activity but that retain normal levels of anti-apoptotic activity are provided. Two examples of such recombinant APC mutants are KKK191-193AAA-APC and RR229 / 230M-APC. APC variants and prodrugs of the invention have the desirable property of being cytoprotective (anti-apoptotic effects), while having significantly reduced risk of bleeding. The invention also provides a method of using the APC variants or prodrugs of the invention to treat subjects who will benefit from APC's cytoprotective activities that are independent of APC's anticoagulant activity. These subjects include patients at risk of damage to blood vessels or tissue in various organs caused, at least in part, by apoptosis. At risk patients include, for example, those suffering (severe) sepsis, ischemia / reperfusion injury, ischemic stroke, acute myocardial infarction, acute or chronic neurodegenerative diseases, or those undergoing organ transplantation or chemotherapy, among other conditions. Methods of screening for variants of recombinant protein C or APC that are useful in accordance with the invention are also provided.

The invention discloses a diterpenoid compound and the preparing method and application thereof. The diterpenoid compound is obtained by using aralia melanocarpa roots as the raw material through extractum extraction, organic solvent extraction, column chromatography on silica gel and high pressure liquid chromatography separation. The molecular formula of the diterpenoid compound is C20H30O3. The name of the diterpenoid compound is 14-oxygen-ent-8(9),15-(14-oxo-ent-pimara-8(9),15-diene-19-oic acid). The structural formula is as shown in the specification. According to the preparing method, aralia melanocarpa roots are used as the raw material, and extractum extraction, organic solvent extraction, column chromatography on silica gel and high pressure liquid chromatography separation are conducted to generate the diterpenoid compound. The diterpenoid compound can be applied to preparation of anti-inflammatory drugs for prevention and / or treatment. The diterpenoid compound is subjected to in-vitro anti-inflammatory activity testing, and experimental results show a good lipopolysaccharide (LPS) restraining effect and a good effect of inducting pulmonary alveolar macrophages (RAW264.7) to generate NO. A new compound or lead compound with high application value can be provided for the medical industry.

The invention provides a celastrol long-chain alcohol ester and the preparation method and the function thereof. The celastrol long-chain alcohol ester has obvious prostate targeting property and stronger anti-tumor and anti-inflammation activity than celastrol. The structural formula is shown on the right, wherein, n is equal to 10-20, m is equal to 2n+1, 2n-1, 2n-3, and the like; wherein, n-hexadecanol, n-decane alcohol, n-dodecanol, n-stearyl alcohol and oleic alcohol are representational.

The invention relates to the field of cosmetics, and particularly relates to an anti-allergic soothing composition and an anti-allergic soothing emulsion and a preparation method thereof. The anti-allergic soothing composition mainly comprises a first active component, stephania tetrandra extract, theanine and epigallocatechin gallate in weight ratio of 0.3-1.5:0.1-0.5:0.8-1.2:0.8-1.2. The first active component includes sophora japonica root extract, glycyrrhiza inflata root extract and scutellaria baicalensis root extract. The components of the anti-allergic soothing composition have a synergistic enhancement effect, and have effects of effectively reducing the adverse effect caused by stimulation, protecting the skin barrier, relieving itching and relieving pain, and soothing the skin;biological polysaccharide and active small molecules are in mutual synergy and slow release for longer lasting action to repair the sensitive skin.

A composition including colostrum or a colostrum-derived product and hyperimmune milk (HIM) or a hyperimmune milk-derived product, in amounts sufficient to provide a combined spectrum of pathogen-binding activity against a broad-spectrum of pathogenic organisms.

The invention discloses an application of a compound to preparation of medicines for treating viral pneumonia, and relates to the technical field of drugs. The technical problem that novel antiviral drugs are deficient in the prior art, can be solved. The compound comprises a purine compound adopting the structure as shown in the formula 1, and / or an anthraquinone derivative adopting the structureas shown in the formula 2. The purine compound adopting the structure as shown in the formula 1, and / or the anthraquinone derivative adopting the structure as shown in the formula 2 both can show predominant effect for resisting viral pneumonia when being separately used or used jointly. Drugs for treating viral pneumonia, are prepared by the compound provided by the invention are more notable inactivity compared with clinical frontline drugs, and are better than drugs of ribavirin, oseltamivir and the like.

Amide derivatives represented by the formula (I):wherein:A is a cycloalkyl group, an aryl group or a heteroaryl group; X is a nitrogen atom or CR17; Y is —NRa—, —(CRbRb′)m-, and the like; m is 0 to 4; and R1 to R17 may be the same or different and each is a hydrogen atom, a halogen atom, a cyano group, a nitro group, a carboxyl group, a formyl group, a hydroxyl group, an ammonium group, an alkyl group optionally having one or more substituents, ZR18 and the like, Z is —O—, —S(O)p-, —S(O)pO—, —NH—, —NR19-, and the like; or R1 and R2 may in combination form a ring, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof may be applied to pharmaceutical use such as anti-inflammatory and analgesic action and the like.

The invention discloses a p-hydroxy phenyl acrylic acid derivative, which has a chemical structure expressed by general formula (I). The invention also discloses application of the p-hydroxy phenyl acrylic acid derivative to preparing COX-2 selective inhibitor medicament, and a pharmaceutical composition for treating and preventing pain, inflammation, rheumatoid arthritis, osteoarthritis or dysmenorrheal diseases, or antiviral and antibacterial pharmaceutical composition for treating and preventing virus and bacterial infection, or pharmaceutical composition for treating and preventing atherosclerosis, thrombosis, apoplexy or ischemia cerebrovascular diseases, wherein the pharmaceutical composition contains the p-hydroxy phenyl acrylic acid derivative or medicinal salt thereof with curative effective dose.

The invention discloses a quinoid chalcone compound with a methyl group at an A ring, and a preparation method and anti-inflammatory activity thereof. The compound has a structure as shown in a general formula (I) which is described in the specification. The preparation method comprises the following steps: (1) synthesizing 2-hydroxy-4,6-dimethoxyacetophenone; (2) synthesizing 2'-hydroxy-4',6'-dimethoxychalcone derivative; (3) synthesizing 2',4',6'-trihydroxy chalcone derivative; and (4) synthesizing the quinoid chalcone compound with a methyl group at the A ring. The compound is simple to prepare and has obvious anti-inflammatory action.

The invention discloses a dammarane type triterpenoid saponin compound, a preparation method thereof and application thereof in preparation of anti-inflammatory drugs. The dammarane type triterpenoidsaponin compound is obtained by separation of cyclocarya paliurus leaves. The preparation method comprises steps of S1, extracting the cyclocarya paliurus leaves by using an alcohol solvent to obtainan extract, wherein the mass ratio of the cyclocarya paliurus leaves to the alcohol solvent is 1: (10-15); S2, separating the extract prepared in the step S1) sequentially by using silica gel column chromatography, MCI gel column choromatography, reversed-phase column choromatography, gel column choromatography and preparation type high performance liquid chromatography to obtain the compound. Thenew compound prepared by the method can suppress release of NO, TNF-alpha, PGE2 and IL-6 in LPS induced RAW264.7 cells, can reduce expression of iNOS, COX-2 and NF-KB / P65 protein, can take on good anti-inflammatory activity and can be used for developing related anti-inflammatory drugs.

The invention relates to rana pleuraden antioxidant peptide and genes and an application thereof, belonging to the technical field of biomedical science. The rana pleuraden antioxidant peptide is thesingle chain polypeptide through genetic encoding of Chinese amphibians rana pleuraden, wherein, the molecular weight is 1653.88 daltons, the isoelectric point is 8.22, and the complete sequence of the rana pleuraden antioxidant peptide is NH2-GIRPTYNRQCEIGF-COOH; the gene for encoding is composed of 316 nucleotides, wherein, the encoding mature part is the 130-171th nucleotide. The synthetic ranapleuraden antioxidant peptide features strong antioxidant activity, can be applicable to the preparation of medicines of skin antioxidant protection and free radicals in vivo elimination, and has theadvantages of simple sequence and convenient synthesis.

The present invention relates to vinyl bridge compound containing sulfonyl radical and diphenyl radical and in the general expression as shown. The present invention also relates to its preparation process and application in preparing medicine for inhibiting epoxy synthase 2 and medicine for treating inflammation and pain of mammal.

The invention discloses a quinoid chalcone compound with an isopentenyl group at an A ring, and a preparation method and anti-inflammatory activity thereof. The compound has a structure as shown in a general formula (I) which is described in the specification. The preparation method comprises the following steps: (1) synthesizing 3,5-dihydroxy-2-acetyl-6,6-diisopentenylcyclohexyl-2,4-dienone; (2) synthesizing 3-hydroxy-5-methoxy-2-acetyl-6,6-diisopentenylcyclohexyl-2,4-dienone; (3) synthesizing a methoxy group protected quinoid chalcone compound with the isopentenyl group at the A ring; and (4) synthesizing the quinoid chalcone compound with the isopentenyl group at the A ring. The compound is simple to prepare and has obvious anti-inflammatory action.

The invention relates to a compound obtained by esterifying carboxylic acid-containing nonsteroidal anti-inflammatory drugs with paeonol and nor-paeonol, a preparation method and application thereof. The compound is obtained by taking the carboxylic acid-containing nonsteroidal anti-inflammatory drugs such as ibuprofen and the like as a raw material and esterifying the raw material with the paeonol through sulfonyl chlorination or with the nor-paeonol by a carbimide method. The compound has anti-inflammatory, and antipyretic and analgesic effects.

Variants (mutants) of recombinant activated protein C (APC) or recombinant protein C (prodrug, capable of being converted to APC) that have substantial reductions in anticoagulant activity but that retain normal levels of anti-apoptotic activity are provided. Two examples of such recombinant APC mutants are KKK191-193AAA-APC and RR229 / 230M-APC. APC variants and prodrugs of the invention have the desirable property of being cytoprotective (anti-apoptotic effects), while having significantly reduced risk of bleeding. The invention also provides a method of using the APC variants or prodrugs of the invention to treat subjects who will benefit from APC's cytoprotective activities that are independent of APC's anticoagulant activity. These subjects include patients at risk of damage to blood vessels or tissue in various organs caused, at least in part, by apoptosis. At risk patients include, for example, those suffering (severe) sepsis, ischemia / reperfusion injury, ischemic stroke, acute myocardial infarction, acute or chronic neurodegenerative diseases, or those undergoing organ transplantation or chemotherapy, among other conditions. Methods of screening for variants of recombinant protein C or APC that are useful in accordance with the invention are also provided.

Disclosed is a method for extracting and purifying active constituents from honeysuckle (Lonicera japonica Thunb.) and its use. More particularly, this invention relates to an extraction and purification method of active constituents including sweroside from for honeysuckle stem (stem of honeysuckle where leaves are removed) by removing tannins, hardly soluble flavonoids, saponins, and the like. Thus obtained active constituents have better anti-inflammatory and analgesic effect, are safer and more stable than the conventional active constituents obtained from honeysuckle flower or honeysuckle leaves, and include sweroside which is an effective active ingredient of anti-inflammatory and analgesic drug.

The invention relates to hyperglycemia-hyperlipidemia-hypertension relieving health protection tea, and aims to solve the problems that the similar health care products are not obvious in hyperglycemia-hyperlipidemia-hypertension relieving effect and are scarce in raw materials. The hyperglycemia-hyperlipidemia-hypertension relieving health protection tea is prepared through the following steps: adding hawthorn fruits and wolfberry fruits into water, soaking for 10-20 minutes, heating and boiling for 5-10 minutes, and filtering to obtain filtrate; then adding coix seeds and licorice roots into the filtrate, soaking for 10-20 minutes, filtering and drying; finally, mixing the dried mixture with frosted folium mori and dicranostigma leptopodum, and grinding to obtain the hyperglycemia-hyperlipidemia-hypertension relieving health protection tea. The hyperglycemia-hyperlipidemia-hypertension relieving health protection tea is composed by taking traditional Chinese medicine theory as the bases; the components contained in the tea such as flavonoids, phenols, vitamins, carotenes, amino acids, mineral substances and organic acids can balance all nutritional ingredients for the human body; synthetic pharmacodynamic effects of all traditional Chinese medicines can be fully utilized to control or intervene hyperglycemia, hyperlipidemia and hypertension; therefore, the hyperglycemia-hyperlipidemia-hypertension relieving health protection tea has the efficacies of enhancing the body vigor, nursing the health, nourishing the vitality, recovering the langerhans gland function, relieving hyperglycemia, hyperlipidemia and hypertension, and diminishing the inflammation.

The invention belongs to the technical field of medicine and discloses a preparation method of an oxygen bridge dicycloheptene compound containing a resveratrol group. One of a 3-(4-hydroxyphenyl)-4-(((E)-3, 5-dihydroxystyryl)phenyl)furan compound and a 3, 4-bis(4-hydroxy-phenyl)furan compound and one of a vinylsulfonate and a vinylsulfonate derivative as raw materials undergo a reaction without a catalyst at 90 DEG C for 8h to produce the oxygen bridge dicycloheptene compound containing a resveratrol group. The oxygen bridge dicycloheptene compound has an action method different from that of the existing anti-breast cancer drug tamoxifen. The oxygen bridge dicycloheptene compound can effectively inhibit growth of breast cancer cells MCF-7 and triple-negative breast cancer cells MDA-MB-231, has good anti-inflammatory activity and has an application prospect in breast cancer treatment.

The invention relates to a polysaccharide acylate and a preparation method thereof. The polysaccharide acylate is represented by a general formula (I), wherein R1 is COCH3 or SO3<->, R2 is H or SO3<->, R3 is COR, R4 is COR or SO3<->, n is an integer in a range of 2 to 16, and R is an alkyl group. The polysaccharide acylate provided by the invention has strong antineoplastic and anti-inflammatory activity and a clear and definite structure, and the preparation method for the polysaccharide acylate is controllable.

The invention discloses a Pangdahai polyoses and a preparation method thereof. The method comprises Pangdahai materials which are degreased and pretreated by ethanol are added with water to be treated by ultrasonication, and then is heated up to 55-65 DEG C to be extracted; after that the extracting solution is concentrated, processed by ethanol precipitation and purified according to the conventional method. By adopting ultrasonication and water bath extraction with lower temperature, the obtained Pangdahai water soluble polyoses has higher yield and purity as well as better anti-inflammation activity.

The invention discloses a chemical acceptable salt and solvent complex or hydrate and composition and application with substituted [1,3,5] triazine compound, which is characterized by the following: displaying obvious EGFR enzyme inhibiting activity and tumour-proof activity in a series of sieving experiment.

The invention discloses a chitosan oligosaccharide-N-linalool copolymer and a preparation method and application thereof. The preparation method of the copolymer comprises the following steps: (1) performing bromination reaction on linalool and phosphorus tribromide at a certain temperature to obtain faint yellow oily liquid linaloyl bromide; and (2) mixing and reacting a certain amount of linaloyl bromide and chitosan oligosaccharide, and treating to obtain the chitosan oligosaccharide-N-linalool copolymer. The alkylation reaction is performed on linalool with anti-inflammatory activity and C2-site active amino of chitosan oligosaccharide, the preparation process and the purification process are simple, and the obtained chitosan oligosaccharide-N-linalool copolymer has good water solubility, thermal stability and anti-inflammatory activity and has good application prospects in the fields of food, medicine, cosmetics, agriculture and the like.

The present invention relates to the use of lignan compounds for treating or preventing an inflammatory disease. More particularly, it relates to a method for preventing or treating an inflammatory disease, comprising administering to a subject in need thereof an effective amount of macelignan represented by Chemical Formula I or a pharmaceutically acceptable salt thereof. The lignan compound has the effect of inhibiting inflammatory reactions by inhibiting the production or expression of inflammation mediators NO, iNOS, PGE2, COX-2 and TNF-α and by treating or preventing inflammatory disease in vivo. Accordingly, the lignan compound or a Myristica fragrans extract will be highly useful for the treatment or prevention of an inflammatory disease.

The invention relates to a method to produce kuhseng omniflavone and flavone salt that mixes kuh-seng and acid water as 1: 5-10 at 10-40 degree centigrade, fully distills biology alkali, filtering, mixing the residue with solvent according 1g: 4-12ml, distilling, filtering, the filtrate could be treated to gain kuhseng omniflavone and flavone. The invention has advantages of low cost raw material, simple technology, etc.